Iterum Therapeutics PLC Stock Math Transform Exponential Price Movement
| ITRM Stock | USD 0.17 -0.01 -5.56% |
| Symbol |
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Iterum Therapeutics PLC Price Movement is a mathematical transformation function to describe exponentially increasing price patterns.
Iterum Therapeutics Technical Analysis Modules
Most technical analysis of Iterum Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Iterum from various momentum indicators to cycle indicators. When you analyze Iterum charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. As a micro-cap equity, Iterum Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 16.21, P/B of 0.43. Iterum Therapeutics has a market cap of 9.19 M, P/E of 16.21, ROE of -5.56%.
Methodology
Unless otherwise specified, financial data for Iterum Therapeutics PLC is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Iterum (USA Stocks:ITRM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The data underlying this report is sourced from public filings and market reference sources, including filings and releases published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Some updates may be delayed based on publication cadence. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Iterum Therapeutics PLC may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardAlign your values with your investing style
Using Iterum Therapeutics PLC inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Thematic Opportunities
Explore Investment Opportunities
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Picks Invested few shares | |
 | Hedge Favorites Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Blockchain Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Investor Favorites Invested few shares | |
 | Video Games Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Advertising Invested few shares | |
 | Social Domain Invested few shares | |
 | Warren Buffett Holdings Invested over 20 shares | |
More Resources for Iterum Stock Analysis
Reviewing Iterum Therapeutics PLC commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Iterum Stock:Iterum Therapeutics has a market cap of 9.19 M, operating margin of -19.82%, ROE of -5.56%. See Risk vs Return Analysis for portfolio-level analysis. This suggests a position in Iterum Therapeutics PLC within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Analysis related to Iterum Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Earnings Share -0.72 | Revenue Per Share | Quarterly Revenue Growth -1.00 | Return On Assets | Return On Equity |
Investors evaluate Iterum Therapeutics PLC using market value and book value, each describing different facets of the business. Iterum Therapeutics' market capitalization is 9.19 M. A P/B ratio of 0.43 suggests Iterum Therapeutics trades near or below book value. Enterprise value stands at 31.94 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Iterum Therapeutics differs from its quoted price, since each reflects a different lens. For Iterum Therapeutics, key inputs include a P/E ratio of 16.21, a P/B ratio of 0.43, and ROE of -5.56%. Trading price represents the transaction level agreed by market participants.